Detalhe da pesquisa
1.
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.
Nature
; 602(7897): 503-509, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35110735
2.
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.
Nature
; 558(7709): 307-312, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29849141
3.
Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.
Nature
; 612(7941): E22, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477542
4.
Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals.
Mol Ther
; 29(2): 626-635, 2021 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186691
5.
Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.
Blood
; 132(10): 1022-1026, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29925499
6.
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.
Gastroenterology
; 155(1): 29-32, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567081
7.
Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor.
PLoS Pathog
; 13(10): e1006613, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29023549
8.
Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.
Mol Ther
; 26(1): 269-279, 2018 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29203150
9.
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.
Blood Adv
; 8(9): 2182-2192, 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38386999
10.
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Nat Med
; 30(4): 984-989, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266761
11.
Unedited allogeneic iNKT cells show extended persistence in MHC-mismatched canine recipients.
Cell Rep Med
; 4(10): 101241, 2023 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37852175
12.
Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma.
Cancer Res Commun
; 3(5): 821-829, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37377890
13.
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy.
Blood Cancer Discov
; 4(2): 118-133, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36413381
14.
The dynamic role of cardiac myosin binding protein-C during ischemia.
J Mol Cell Cardiol
; 52(5): 1145-54, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22281395
15.
PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response.
Front Immunol
; 13: 872756, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603165
16.
PSMA-targeting TGFß-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
Nat Med
; 28(4): 724-734, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35314843
17.
Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy.
J Am Acad Dermatol
; 75(5): 1054-1057, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27745631
18.
Neutrophil alpha-defensins cause lung injury by disrupting the capillary-epithelial barrier.
Am J Respir Crit Care Med
; 181(9): 935-46, 2010 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20093642
19.
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
J Clin Invest
; 131(16)2021 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34396987
20.
CRISPR-engineered T cells in patients with refractory cancer.
Science
; 367(6481)2020 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32029687